8-K: Current report filing
Published on October 13, 2005
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 11, 2005
Access Pharmaceuticals, Inc.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-9314 83-0221517
- ------------------------ ------------------------ -------------------
(State of Incorporation) (Commission File Number) (I.R.S. Employer
Identification No.)
2600 Stemmons Freeway, Suite 176, Dallas, Texas 75207
----------------------------------------------- ---------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (214) 905-5100
--------------
Item 7.01 Regulation FD Disclosure
------------------------
Access Pharmaceuticals, Inc. issued a press release on October 11, 2005, a
copy of which is attached as Exhibit 99.1 to this report and incorporated
herein by this reference, in which it announced the sale of its oral care
business and restructuring the company to focus on oncology therapeutics.
This information shall not be deemed to be "filed" for the purposes
of Section 18 of the Securities Exchange Act of 1934 and shall not be
deemed to be incorporated by reference in any filing under the Securities
Act of 1933.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Access Pharmaceuticals, Inc.
(Registrant)
By: /s/ Stephen B. Thompson
------------------
Stephen B. Thompson
Vice President and
Chief Financial Officer
Dated October 11, 2005
3
EXHIBIT INDEX
Exhibit
Number Description
- ------- ------------
99.1 Press Release, date October 11, 2005
4